Journal of clinical psychopharmacology · 2026
Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept Trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maekawa Renan Massanobu, Guerra Lorena T L, Villanova Bianca, de Paula Caio Cesar, Zacharias Anna Beatriz Vicentini, Rodrigues Lucas Silva, Reis José Augusto Silva, Rossi Giordano Novak, Bouso José Carlos, Hallak Jaime Eduardo Cecilio, Dos Santos Rafael Guimarães
Аннотация
BACKGROUND: Depressive and anxiety symptoms are highly prevalent among patients with cancer and are associated with substantial reductions in quality of life. However, effective therapeutic options remain limited. Ayahuasca, a serotonergic psychedelic traditionally used in Amazonian ritual contexts, has shown rapid antidepressant and anxiolytic effects following a single administration in previous studies.
METHODS: This single-blind study included 6 female participants. Depressive and anxiety symptoms were evaluated at baseline and at 1, 2, 3 weeks and 3 months following the dosing session using the Beck Depression Inventory-II, the Patient Health Questionnaire-9 and the Beck Anxiety Inventory scales.
FINDINGS: Results indicated significant reductions in depressive and anxiety symptoms lasting up to 3 weeks following administration, with no serious adverse effects reported. Greater improvements in depressive symptoms were associated with more intense affective and subjective psychedelic experiences during the session.
CONCLUSIONS: These preliminary findings suggest that ayahuasca may produce sustained improvements in mood and anxiety symptoms in patients with cancer. However, the small sample size and lack of a control group limit generalization, underscoring the need for larger, placebo-controlled studies.
METHODS: This single-blind study included 6 female participants. Depressive and anxiety symptoms were evaluated at baseline and at 1, 2, 3 weeks and 3 months following the dosing session using the Beck Depression Inventory-II, the Patient Health Questionnaire-9 and the Beck Anxiety Inventory scales.
FINDINGS: Results indicated significant reductions in depressive and anxiety symptoms lasting up to 3 weeks following administration, with no serious adverse effects reported. Greater improvements in depressive symptoms were associated with more intense affective and subjective psychedelic experiences during the session.
CONCLUSIONS: These preliminary findings suggest that ayahuasca may produce sustained improvements in mood and anxiety symptoms in patients with cancer. However, the small sample size and lack of a control group limit generalization, underscoring the need for larger, placebo-controlled studies.